The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease

Chen, Chiung Yu; Tsai, Wan-Ting; Lin, Po Ju; Shiesh, Shu Chu

doi:10.1515/cclm.2011.675

Cited by 38 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are concerns about tissue-specificity of IMA, as it has been suggested that IMA is a biomarker for other oxidative stress or ischemia-related diseases 19. The possible role of IMA was confirmed in previous studies 4,6,10–12. In the present study, the T2DK patients had significantly poorer glycemic control, which was associated with an increase in inflammatory and oxidative stress biomarkers.…”

Section: Discussionsupporting

confidence: 82%

Evaluation of Ischemia-Modified Albumin and C-Reactive Protein in Type 2 Diabetics with and without Ketosis

Yao

Wen

et al. 2012

Biomark�Insights

View full text Add to dashboard Cite

OverviewTo investigate whether serum ischemia-modified albumin or C-reactive protein is reliable for predicting type 2 diabetic patients with ketosis.ApproachOne hundred and four diabetic patients, 48 with diabetic ketosis, and 33 controls were enrolled in the study. Serum ischemia-modified albumin and C-reactive protein were measured and evaluated for their ability to distinguish diabetic ketosis.ResultsCompared to the controls, the ischemia-modified albumin and C-reactive protein levels were higher in patients with diabetic ketosis and type 2 diabetes at the baseline. The levels of ischemia-modified albumin were higher in patients with type 2 diabetes than in the controls. C-reactive protein and ischemia-modified albumin levels were reduced after insulin treatment. The level of ischemia-modified albumin was an independent risk marker for diabetic ketosis (OR = 1.085, P = 0.008, 95% CI: 1.022–1.152). Receiver operating characteristic curves revealed that the areas under the curve were 0.917 for the modified albumin and 0.357 for C-reactive protein.ConclusionThis study indicates that ischemia-modified albumin was significantly associated with diabetic ketosis and was more sensitive than C-reactive protein in reflecting diabetic ketosis.

show abstract

Section: Discussionsupporting

confidence: 82%

Evaluation of Ischemia-Modified Albumin and C-Reactive Protein in Type 2 Diabetics with and without Ketosis

Yao

Wen

et al. 2012

Biomark�Insights

View full text Add to dashboard Cite

show abstract

“…Mentese et al (30) reported that IMA was an appropriate ischaemiareperfusion injury marker of testicular damage during acute and chronic periods. In addition, IMA was reported to be an important indicator of liver function (10). We also observed that the antioxidant RV attenuated IMA levels in parallel with changes in liver enzymes and bilirubin.…”

Section: Discussionsupporting

confidence: 63%

Resveratrol Attenuates Both Small Bowel and Liver Changes in Obstructive Jaundice

et al. 2014

View full text Add to dashboard Cite

“…Therefore continuous liver cells damage, leads to a deficiency in the synthesis of cholinesterase enzyme. In agreement with Chen et al (2011) serum cholinesterase is an excellent biomarker of cirrhosis with good sensitivity and specificity. It shows good correlation with serum albumin and PT.…”

Section: Parameter Albumin (G/l) Prothrombin Time (S)supporting

confidence: 56%

Serum cholinesterase as liver function test in cirrhotic patients at Soba Teaching hospital, Khartoum, Sudan

Mohamed¹,

Amanullah²,

Amanvermez³

et al. 2017

Int Res J Med Med Sci

View full text Add to dashboard Cite

It is suggested that plasma cholinesterase level is affected by liver cirrhosis due to hepatocyte injury. The objective of this study was to determine cholinesterase values in association with albumin and prothrombin during both the compensated and decompensated stages in cirrhotic patients. A total of 150 consecutive episodes of liver cirrhotic patients, aged (68.9 ± 10 years) admitted to the hospital between June 2015 and December 2015 were studied. They were classified into subgroups according to severity and the stages of disease into group A (compensated stage) and group B (decompensated stage), each containing 75 patients. Fifty apparently healthy participants aged 64.5 ± 13 years were recruited as controls. Blood samples were drawn and targeted parameters were assessed using commercial kits according to the manufacturer's guide. SPSS package was used for data analysis. There was a significant difference in the mean serum cholinesterase activity, albumin level and prothrombin time of cases and controls. The mean serum cholinesterase value of compensated cirrhotic patients was 3143.83 ± 1583.44 IU/L and it was significantly higher (p = 0.000) than that of decompensated cirrhotic patients (1895.32 ± 531.79 IU/L). There was a strong negative correlation between serum cholinesterase activity and prothrombin time (r = -0.580, p = 0.000) and a strong positive correlation between serum cholinesterase activity and albumin concentration (r = 0.617, p = 0.00). The results conclude that, cholinesterase level reflects liver cell conditions wherein low levels indicate hepatocellular damage. In addition, its levels are stable and not easily affected by medications that are given for cirrhotic patients thus, can be used as a marker for the diagnosis and prognosis of liver damage along with prothrombin time and albumin.

show abstract

The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease

Abstract: IMAR, reflecting liver function and oxidative stress, is a more objective liver function test as it was not affected after a 3-day albumin infusion. More investigations, however, are needed to validate the use of IMAR in cases of chronic liver disease.

Cited by 38 publications

References 21 publications

Evaluation of Ischemia-Modified Albumin and C-Reactive Protein in Type 2 Diabetics with and without Ketosis

Evaluation of Ischemia-Modified Albumin and C-Reactive Protein in Type 2 Diabetics with and without Ketosis

Resveratrol Attenuates Both Small Bowel and Liver Changes in Obstructive Jaundice

Serum cholinesterase as liver function test in cirrhotic patients at Soba Teaching hospital, Khartoum, Sudan

Contact Info

Product

Resources

About